全文获取类型
收费全文 | 895603篇 |
免费 | 73310篇 |
国内免费 | 1946篇 |
专业分类
耳鼻咽喉 | 13292篇 |
儿科学 | 25703篇 |
妇产科学 | 25726篇 |
基础医学 | 128498篇 |
口腔科学 | 26221篇 |
临床医学 | 78717篇 |
内科学 | 170912篇 |
皮肤病学 | 17537篇 |
神经病学 | 73349篇 |
特种医学 | 36543篇 |
外国民族医学 | 171篇 |
外科学 | 140964篇 |
综合类 | 25295篇 |
现状与发展 | 2篇 |
一般理论 | 283篇 |
预防医学 | 70655篇 |
眼科学 | 21531篇 |
药学 | 66827篇 |
中国医学 | 1638篇 |
肿瘤学 | 46995篇 |
出版年
2018年 | 7740篇 |
2015年 | 8221篇 |
2014年 | 11873篇 |
2013年 | 18129篇 |
2012年 | 24399篇 |
2011年 | 25688篇 |
2010年 | 14909篇 |
2009年 | 14069篇 |
2008年 | 24338篇 |
2007年 | 26683篇 |
2006年 | 26540篇 |
2005年 | 26119篇 |
2004年 | 25633篇 |
2003年 | 24713篇 |
2002年 | 23875篇 |
2001年 | 36362篇 |
2000年 | 36983篇 |
1999年 | 31446篇 |
1998年 | 9719篇 |
1997年 | 8934篇 |
1996年 | 8856篇 |
1995年 | 8368篇 |
1994年 | 8059篇 |
1992年 | 27044篇 |
1991年 | 26452篇 |
1990年 | 25963篇 |
1989年 | 25010篇 |
1988年 | 23559篇 |
1987年 | 23192篇 |
1986年 | 22061篇 |
1985年 | 21450篇 |
1984年 | 16751篇 |
1983年 | 14337篇 |
1982年 | 9317篇 |
1981年 | 8617篇 |
1980年 | 8090篇 |
1979年 | 17031篇 |
1978年 | 12393篇 |
1977年 | 10470篇 |
1976年 | 9548篇 |
1975年 | 10383篇 |
1974年 | 12887篇 |
1973年 | 12382篇 |
1972年 | 11750篇 |
1971年 | 10817篇 |
1970年 | 10324篇 |
1969年 | 9993篇 |
1968年 | 8993篇 |
1967年 | 8327篇 |
1966年 | 7737篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
5.
6.
7.
8.
Simeprevir added to peginterferon and ribavirin lessens time with fatigue,depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST‐1, QUEST‐2 and PROMISE studies 下载免费PDF全文
J. Scott L. Gilles M. Fu E. Brohan C. Panter R. Arbuckle W. Jessner M. Beumont 《Journal of viral hepatitis》2015,22(8):639-650
The value of adding simeprevir (SMV) vs placebo (PBO) to peginterferon and ribavirin (PR) for treatment of chronic hepatitis C virus infection was examined using patient‐reported outcomes (PROs); further, concordance of PROs with virology endpoints and adverse events (AEs) was explored. Patients (n = 768 SMV/PR, n = 393 PBO/PR) rated fatigue (FSS), depressive symptoms (CES‐D) and functional impairment (WPAI: Hepatitis C Productivity, Daily Activity and Absenteeism) at baseline and throughout treatment in three randomised, double‐blind trials comparing the addition of SMV or PBO during initial 12 weeks of PR. PR was administered for 48 weeks (PBO group) and 24/48 weeks (SMV group) using a response‐guided therapy (RGT) approach. Mean PRO scores (except Absenteeism) worsened from baseline to Week 4 to the same extent in both groups but reverted after Week 24 for SMV/PR and only after Week 48 for PBO/PR. Accordingly, there was a significantly lower area under the curve (baseline–Week 60, AUC60) and fewer weeks with clinically important worsening of scores in the SMV/PR group at any time point. Incidences of patients with fatigue and anaemia AEs were similar in both groups, but FSS scores showed that clinically important increases in fatigue lasted a mean of 6.9 weeks longer with PBO/PR (P < 0.001). PRO score subgroup analysis indicated better outcomes for patients who met the criteria for RGT or achieved sustained virological response 12 weeks post‐treatment (SVR12); differences in mean PRO scores associated with fibrosis level were only observed with PBO/PR. Greater efficacy of SMV/PR enabled reduced treatment duration and reduced time with PR‐related AEs without adding to AE severity. 相似文献
9.
10.
Benyam Kinde Harrison W. Gabel Caitlin S. Gilbert Eric C. Griffith Michael E. Greenberg 《Proceedings of the National Academy of Sciences of the United States of America》2015,112(22):6800-6806
DNA methylation at CpG dinucleotides is an important epigenetic regulator common to virtually all mammalian cell types, but recent evidence indicates that during early postnatal development neuronal genomes also accumulate uniquely high levels of two alternative forms of methylation, non-CpG methylation and hydroxymethylation. Here we discuss the distinct landscape of DNA methylation in neurons, how it is established, and how it might affect the binding and function of protein readers of DNA methylation. We review studies of one critical reader of DNA methylation in the brain, the Rett syndrome protein methyl CpG-binding protein 2 (MeCP2), and discuss how differential binding affinity of MeCP2 for non-CpG and hydroxymethylation may affect the function of this methyl-binding protein in the nervous system. 相似文献